Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.35 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 6/20 | 0.32 |
| ▸ | CA2 | P00918 | 6/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137769 | 0.89 | MEN1 (0.37) | MAP2K1 | |
| SCHEMBL6138060 | 0.86 | MAP2K1 (0.34) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 | |
| SCHEMBL6138007 | 0.74 | MAP2K1 (0.33) | MAP2K1MAP2K2CA2 | |
| SCHEMBL6137728 | 0.74 | MAP2K1 (0.40) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 | |
| SCHEMBL6139021 | 0.73 | SOS1 (0.36) | CA1CA2CA9 | |
| SCHEMBL6266645 | 0.72 | MAP2K1 (0.64) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 | |
| SCHEMBL6137890 | 0.72 | MAP2K1 (0.41) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 | |
| SCHEMBL6138126 | 0.72 | MAP2K1 (0.40) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 | |
| SCHEMBL6138011 | 0.71 | MAP2K1 (0.39) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 | |
| SCHEMBL6266420 | 0.71 | MAP2K1 (0.53) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144394-B1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER LAMBERT CO (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6545030-B1 | Treating proliferative diseases, the sequelae of a stroke or heart failure, xenograft rejection, osteoarthritis, HIV, rheumatoid arthritis, cystic fibrosis, hepatomegaly, shock,cardiomegaly, Alzheimer's disease, diabetes | WARNER-LAMBERT COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20030004193-A1 | 1-Heterocycle substituted diarylamines | BARRETT STEPHEN DOUGLAS (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1202732-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144394-A1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005391-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042029-A1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004193-A1 | 1-Heterocycle substituted diarylamines | IDH3A, CCNA1, HCCS | MAP2K1 3800/4885RAF1 1596/4885PDGFRB 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.